Businesswire reports emerging biotechnology company AXONIS Therapeutics, Inc. has secured an additional $5 million in funding and provided an update on progress advancing novel therapeutics for neurological disorders.
The Massachusetts Life Sciences Center (MLSC) named Axonis, Inc. CEO Joanna Stanicka a 2020 winners of the Massachusetts Next Generation Initiative.
AXONIS are delighted to be awarded the Astellas-sponsored “Golden Ticket Competition.” A Golden Ticket award offers entrepreneurial scientists or emerging biotechnology startups one-year usage of LabCentral’s state-of-the-art lab facility in Cambridge, Massachusetts, as well as access to Astellas’ research and development (R&D) capabilities and business leaders.
May 28: AXONIS Therapeutics, Inc. announces the close of the first tranche of a $4 million Seed Preferred financing.
The International Space Station (ISS) U.S. National Laboratory and Boeing [NYSE: BA] have partnered for the sixth consecutive year to provide up to $500,000 in grants to innovative startups through the MassChallenge (Boston) startup accelerator program. The two startup companies awarded a 2019 MassChallenge “Technology in Space Prize,” Encapsulate LLC and Axonis, Inc., will have […]
Congratulations to Axonis, the winner of our latest Innovation Prize in Boston for their work in neuro-restorative research in spinal cord injury. We’re pleased to award them one year of prepaid bench space at LabCentral. Learn more about our #InnovationPrize